Prostaglandin endoperoxide H synthases (PGHSs) 1 and 2, also known as cyclooxygenases (COXs), catalyze the oxygenation of arachidonic acid (AA) in the committed step in prostaglandin (PG) biosynthesis. PGHSs are homodimers that display half of sites COX activity with AA; thus, PGHSs function as conformational heterodimers. Here we show that, during catalysis, fatty acids (FAs) are bound at both COX sites of a PGHS-2 dimer. Initially, an FA binds with high affinity to one COX site of an unoccupied homodimer. This monomer becomes an allosteric monomer, and it causes the partner monomer to become the catalytic monomer that oxygenates AA. A variety of FAs can bind with high affinity to the COX site of the monomer that becomes the allosteric monomer. Importantly, the efficiency of AA oxygenation is determined by the nature of the FA bound to the allosteric monomer. When tested with low concentrations of saturated and monounsaturated FAs (e.g. oleic acid), the rates of AA oxygenation are typically 1.5-2 times higher with PGHS-2 than with PGHS-1. These different kinetic behaviors of PGHSs may account for the ability of PGHS-2 but not PGHS-1 to efficiently oxygenate AA in intact cells when AA is a small fraction of the FA pool such as during "late phase" PG synthesis. Prostaglandin endoperoxide H synthases (PGHSs)2 also known generically as cyclooxygenases (COXs) convert arachidonic acid (AA), two O 2 molecules, and two electrons from one or more unknown reductants to prostaglandin H 2 (PGH 2 ) (1-5). The conversion involves two steps. First, the cyclooxygenase activity of PGHSs catalyzes the introduction of two O 2 molecules into the AA backbone forming prostaglandin G 2 . Prostaglandin G 2 can be reduced to PGH 2 by the peroxidase (POX) activity of the enzyme. There is a functional interplay between the COX and POX sites in that the heme group at the POX site needs to be oxidized by a peroxide to oxidize Tyr-385 in the active COX site to a tyrosyl radical. The Tyr-385 radical abstracts the 13-proS hydrogen from AA to initiate the COX reaction in the rate-determining step.PGHSs are homodimers with monomer molecular masses of ϳ72 kDa (1). Previous studies have indicated that there is crosstalk between the COX activities of the partner monomers and that the COX function exhibits half of sites activity with AA (6). That is, only one monomer of a dimer catalyzes AA oxygenation at any given time. Furthermore, the binding of inhibitors of the 2-phenylpropionic acid class such as flurbiprofen (FBP) or ibuprofen to one COX site is sufficient to inhibit all COX activity of a dimer (6, 7). The existence of half of sites activity establishes that PGHSs are conformational heterodimers when the rate-determining step in catalysis occurs.Despite exhibiting half of sites activity, there has been little evidence for cooperativity between the two COX sites during substrate turnover, and no physiological importance has been attached to the half of sites activity. However, we recently found in testing PGHS-2 with AA and another COX substr...
Prostaglandin endoperoxide H synthases (PGHSs), also called cyclooxygenases (COXs), convert arachidonic acid (AA) to PGH2. PGHS-1 and PGHS-2 are conformational heterodimers, each composed of an (Eallo) and a catalytic (Ecat) monomer. Previous studies suggested that the binding to Eallo of saturated or monounsaturated fatty acids (FAs) that are not COX substrates differentially regulate PGHS-1 versus PGHS-2. Here, we substantiate and expand this concept to include polyunsaturated FAs known to modulate COX activities. Non-substrate FAs like palmitic acid bind Eallo of PGHSs stimulating human (hu) PGHS-2 but inhibiting huPGHS-1. We find the maximal effects of non-substrate FAs on both huPGHSs occurring at the same physiologically relevant FA/AA ratio of ∼20. This inverse allosteric regulation likely underlies the ability of PGHS-2 to operate at low AA concentrations, when PGHS-1 is effectively latent. Unlike FAs tested previously, we observe that C-22 FAs, including ω-3 fish oil FAs, have higher affinities for Ecat than Eallo subunits of PGHSs. Curiously, C-20 ω-3 eicosapentaenoate preferentially binds Ecat of huPGHS-1 but Eallo of huPGHS-2. PGE2 production decreases 50% when fish oil consumption produces tissue EPA/AA ratios of ≥0.2. However, 50% inhibition of huPGHS-1 itself is only seen with ω-3 FA/AA ratios of ≥5.0. This suggests that fish oil-enriched diets disfavor AA oxygenation by altering the composition of the FA pool in which PGHS-1 functions. The distinctive binding specificities of PGHS subunits permit different combinations of non-esterified FAs, which can be manipulated dietarily, to regulate AA binding to Eallo and/or Ecat thereby controlling COX activities.
This article is available online at http://www.jlr.org formation of 1-, 2-and 3-series prostaglandins from dihomo-␥ -linolenic acid (DHLA), arachidonic acid (AA), and eicosapentaenoic acid (EPA), respectively. PGHSs are commonly called cyclooxygenases (COXs). There are two PGHS isoforms encoded by different genes and known as PGHS-1 and PGHS-2 or COX-1 and COX-2.PGHSs catalyze both COX and peroxidase (POX) reactions that occur at distinct physical sites on the enzymes but sites that are electronically and mechanistically linked. The COX is a bis -oxygenase. During the COX reaction with AA, two O 2 molecules are introduced into the carbon backbone of the substrate, and various rearrangements occur that yield a bicyclic endoperoxide called prostaglandin G 2 (PGG 2 ). The 15-hydroperoxyl group of PGG 2 can be reduced to prostaglandin H 2 by the POX activity. The POX and COX activities of PGHSs require hydroperoxides ( 4, 6 ). Hydroperoxides are immediate substrates for the POX activity of PGHS. Oxidation of the heme group at the POX site during the reduction of peroxides leads to the formation of a tyrosyl radical in the COX site. The tyrosyl radical abstracts a hydrogen from AA in the initial step in COX catalysis. Ovine (ov) PGHS-1 prefers primary and secondary alkyl hydroperoxides to H 2 O 2 or bulky peroxides like t -butyl hydroperoxide ( 7,8 ).PGHSs are targets of COX inhibitors, including nonspecifi c nonsteroidal anti-infl ammatory drugs (nsNSAIDs) that inhibit both isoforms and COX-2 inhibitors that are relatively more specifi c for the COX activity of PGHS-2; the more recently developed COX-2 inhibitors are often called coxibs. Mechanistically, COX inhibitors fall into two broad categories, time-dependent and time-independent/ Abstract Recombinant human prostaglandin endoperoxide H synthase-1 (huPGHS-1) was characterized. huPGHS-1 has a single high-affi nity heme binding site per dimer and exhibits maximal cyclooxygenase (COX) activity with one heme per dimer. Thus, huPGHS-1 functions as a conformational heterodimer having a catalytic monomer (E cat ) with a bound heme and an allosteric monomer (E allo ) lacking heme. The enzyme is modestly inhibited by common FAs including palmitic, stearic, and oleic acids that are not COX substrates. Studies of arachidonic acid (AA) substrate turnover at high enzyme-to-substrate ratios indicate that nonsubstrate FAs bind the COX site of E allo to modulate the properties of E cat . Nonsubstrate FAs slightly inhibit huPGHS-1 but stimulate huPGHS-2, thereby augmenting AA oxygenation by PGHS-2 relative to PGHS-1. Nonsubstrate FAs potentiate the inhibition of huPGHS-1 activity by time-dependent COX inhibitors, including aspirin, all of which bind E cat . Surprisingly, preincubating huPGHS-1 with nonsubstrate FAs in combination with ibuprofen, which by itself is a time-independent inhibitor, causes a short-lived, time-dependent inhibition of huPGHS-1. Thus, in general, having a FA bound to E allo stabilizes time-dependently inhibited conformations of E cat . We speculate that...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.